These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1030425)

  • 41. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rev Roum Virol; 1993; 44(1-2):3-7. PubMed ID: 8043476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of freeze-drying on the potency and stability of live varicella virus vaccine.
    Bennett PS; Maigetter RZ; Olson MG; Provost PJ; Scattergood EM; Schofield TL
    Dev Biol Stand; 1992; 74():215-21. PubMed ID: 1317307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
    Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
    Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studies on yellow fever vaccine. II--Stability of the reconstituted product.
    Lopes Ode S; Guimarães SS; de Carvalho R
    J Biol Stand; 1988 Apr; 16(2):71-6. PubMed ID: 3372544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological studies with group B arthropod-borne viruses. VI. Hemagglutination-inhibiting antibody responses to 17D yellow fever vaccine in human subjects with different degrees of complexity of pre-vaccination group B virus experience.
    Hatgi JN; Wisseman CL; Rosenzweig EC; Harrington BR; Kitaoka M
    Am J Trop Med Hyg; 1966 Jul; 15(4):601-10. PubMed ID: 5941178
    [No Abstract]   [Full Text] [Related]  

  • 46. [Stability of lyophilized smallpox vaccine after more than 3 years of storage in temperatures of the environment].
    Kühn O
    Z Gesamte Hyg; 1967 Jul; 13(7):487-93. PubMed ID: 5594126
    [No Abstract]   [Full Text] [Related]  

  • 47. Detection of classical swine fever vaccine virus in blood and tissue samples of pigs vaccinated either with a conventional C-strain vaccine or a modified live marker vaccine.
    Koenig P; Hoffmann B; Depner KR; Reimann I; Teifke JP; Beer M
    Vet Microbiol; 2007 Mar; 120(3-4):343-51. PubMed ID: 17147979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Yellow fever vaccine.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1984 Jan; 32(52):679-82, 687-8. PubMed ID: 6419048
    [No Abstract]   [Full Text] [Related]  

  • 49. The thermal stability of yellow fever vaccines.
    Ishak R; Howard CR
    Mem Inst Oswaldo Cruz; 1990; 85(3):339-45. PubMed ID: 2134708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physical characterisation of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage.
    Passot S; Fonseca F; Alarcon-Lorca M; Rolland D; Marin M
    Eur J Pharm Biopharm; 2005 Aug; 60(3):335-48. PubMed ID: 15894475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overcoming the need for a cold chain with conjugated meningococcal Group C vaccine: A controlled, randomized, double-blind study in toddlers on the safety and immunogenicity of Menjugate, stored at room temperature for 6 months.
    Schöndorf I; Banzhoff A; Nicolay U; Diaz-Mitoma F
    Vaccine; 2007 Jan; 25(7):1175-82. PubMed ID: 17095129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stabilisation of BCG vaccines.
    Gheorghiu M; Lagranderie M; Balazuc AM
    Dev Biol Stand; 1996; 87():251-61. PubMed ID: 8854025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term stability of Kallidinogenase Reference Standard].
    Tanimoto T; Fukuda H; Kimura T
    Eisei Shikenjo Hokoku; 1989; (107):119-20. PubMed ID: 2636912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of storage temperature on the stability of Lassa virus complement-fixing antigen.
    Tomori O
    Bull World Health Organ; 1980; 58(2):293-6. PubMed ID: 6772319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stability of measles vaccines.
    Gray A
    Dev Biol Stand; 1978; 41():265-6. PubMed ID: 753655
    [No Abstract]   [Full Text] [Related]  

  • 56. Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods.
    Patois E; Capelle MA; Gurny R; Arvinte T
    Vaccine; 2011 Oct; 29(43):7404-13. PubMed ID: 21803109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of an end-point microassay for yellow fever vaccine.
    Husson van Vliet J
    Biologicals; 1990 Jan; 18(1):25-7. PubMed ID: 2317350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Live viral vaccine potency: an index for assessing the cold chain system.
    Adu FD; Adedeji AA; Esan JS; Odusanya OG
    Public Health; 1996 Nov; 110(6):325-30. PubMed ID: 8979747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies on yellow fever vaccine. III--Dose response in volunteers.
    Lopes Ode S; Guimarães SS; de Carvalho R
    J Biol Stand; 1988 Apr; 16(2):77-82. PubMed ID: 3372545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of various temperatures in relation to time on 17-D Yellow Fever virus vaccines.
    Lucasse C; Visser C
    J Biol Stand; 1978 Jan; 6(1):1-11. PubMed ID: 624735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.